What is NDC 68083-340?

68083-340 is the product NDC for ziprasidone mesylate, Ziprasidone mesylate 20 mg/mL injection, powder, lyophilized, for solution, listed with the FDA by Gland Pharma Limited. It has 1 package NDC, shown above in 10- and 11-digit form.

Gland Pharma Limited, NDC labeler code 68083. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for ziprasidone mesylate?

7 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

ziprasidone mesylate NDC 68083-340

NDC codes

FDA NDC Directory

Product NDC (as listed)68083-340Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68083-0340Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68083-340-01	6808303400168083034001	1 VIAL, SINGLE-DOSE in 1 CARTON (68083-340-01) / 1 mL in 1 VIAL, SINGLE-DOSEMarketed from Dec 26, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): ziprasidone mesylate
Generic name (nonproprietary): ziprasidone mesylate
Active ingredients: Ziprasidone mesylate — 20 mg/mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intramuscular
Labeler: Gland Pharma LimitedNDC labeler code 68083
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 211908
Marketing start: Dec 26, 2019
Listing expires: Dec 31, 2027
Identifiers: Product ID 68083-340_dae5d774-0982-4b2b-8803-02bd0910d228SPL ID dae5d774-0982-4b2b-8803-02bd0910d228SPL set ID 77a10f48-e300-465f-81b5-54be38daa4b3RxCUI 351223UNII 3X6SAX83JZ
Pharmacologic class: Atypical Antipsychotic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N468083034001 followed by a unit qualifier and the quantity

Package 68083-0340-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 13, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions (5.3) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether zipr…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 68083-340

What is NDC 68083-340?: 68083-340 is the product NDC for ziprasidone mesylate, Ziprasidone mesylate 20 mg/mL injection, powder, lyophilized, for solution, listed with the FDA by Gland Pharma Limited. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: ziprasidone mesylate.
What is the active ingredient?: Ziprasidone mesylate.
Who is the labeler?: Gland Pharma Limited, NDC labeler code 68083. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for ziprasidone mesylate?: 7 other product NDCs are listed under this name. See all ziprasidone mesylate NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other ziprasidone mesylate NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
ziprasidone mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	REMEDYREPACK INC.	70518-4755	70518-4755-00
Ziprasidone Mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	STERISCIENCE SPECIALTIES PRIVATE LIMITED	82449-004	82449-0004-0182449-0004-02
ziprasidone mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Novadoz Pharmaceuticals LLC	72205-205	72205-0205-07
ziprasidone mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Dr.Reddy's Laboratories, Inc.	43598-061	43598-0061-58
Ziprasidone Mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	HF Acquisition Co LLC, DBA HealthFirst	51662-1564	51662-1564-03
Ziprasidone Mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Fosun Pharma USA Inc.	72266-160	72266-0160-10
ziprasidone mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Dr.Reddy's Laboratories, Inc.	43598-848	43598-0848-58

Other NDCs under ANDA 211908

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 211908
Product	Strength	Form · route	Labeler	Product NDC
ziprasidone mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	REMEDYREPACK INC.	70518-4755
Ziprasidone Mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	HF Acquisition Co LLC, DBA HealthFirst	51662-1564
ziprasidone mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Dr.Reddy's Laboratories, Inc.	43598-061
Ziprasidone Mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Fosun Pharma USA Inc.	72266-160
Ziprasidone Mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Fosun Pharma USA Inc.	72266-160
ziprasidone mesylate	Ziprasidone mesylate 20 mg/mL	Injection, Powder, Lyophilized, For solutionIntramuscular	Dr.Reddy's Laboratories, Inc.	43598-848